United Therapeutics Stock Investor Sentiment

UTHR Stock  USD 307.24  1.85  0.61%   
Slightly above 54% of United Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding United Therapeutics suggests that many traders are impartial. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over two weeks ago at thelincolnianonline.com         
Access Investment Management LLC Raises Stake in United Therapeutics Co.
news
over two weeks ago at finance.yahoo.com         
United Therapeutics Corporation Among Renaissance Technologies Portfolios Top Stock Picks
Yahoo News
over two weeks ago at insidermonkey.com         
United Therapeutics Corporation Among Renaissance Technologies Portfolios Top Stock Picks
insidermonkey News
over two weeks ago at simplywall.st         
Will Weakness in United Therapeutics Corporations Stock Prove Temporary Given Strong Fundamentals?
Simply Wall St News at Macroaxis
over three weeks ago at thelincolnianonline.com         
Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. Stock
news
over three weeks ago at thelincolnianonline.com         
Hussman Strategic Advisors Inc. Purchases 2,100 Shares of United Therapeutics Co.
news
over three weeks ago at techcrunch.com         
Disposition of 7700 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3
news
over three weeks ago at gurufocus.com         
United Therapeutics Corp to Announce Q4 and Full Year 2024 Financial Results
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
Indivior PLC Q4 Earnings Meet Estimates
zacks News
over three weeks ago at finance.yahoo.com         
Indivior PLC Q4 Earnings Meet Estimates
Yahoo News
over three weeks ago at businesswire.com         
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before...
businesswire News
over three weeks ago at finance.yahoo.com         
Disposition of 400 shares by Michael Benkowitz of United Therapeutics at 373.6725 subject to Rule 16...
Yahoo News
over three weeks ago at www.macroaxis.com         
Disposition of 400 shares by Michael Benkowitz of United Therapeutics at 373.6725 subject to Rule 16...
Macroaxis News
over three weeks ago at www.macroaxis.com         
Disposition of 196 shares by Michael Benkowitz of United Therapeutics at 360.8488 subject to Rule 16...
Macroaxis News
over a month ago at finance.yahoo.com         
United Therapeutics Buy, Sell, or Hold Post Q3 Earnings?
Yahoo News
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.

United Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.